Kalvista Pharmaceuticals: Intend to Reduce Spending on Discovery & Preclinical Activities by More Than 75%, to Less Than $5 Mln per Year
Kalvista Pharmicals:打算将研发和临床前活动的支出减少75%以上,至每年不到500万美元
Kalvista Pharmaceuticals: Intend to Reduce Spending on Discovery & Preclinical Activities by More Than 75%, to Less Than $5 Mln per Year
Kalvista Pharmicals:打算将研发和临床前活动的支出减少75%以上,至每年不到500万美元
使用浏览器的分享功能,分享给你的好友吧